Strata Critical Medical (SRTA) Gross Profit (2021 - 2026)

Strata Critical Medical (SRTA) has 6 years of Gross Profit data on file, last reported at $14.1 million in Q1 2026.

• Quarterly Gross Profit rose 100.16% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 113.84% YoY) and the FY2025 annual result came in at $41.1 million, up 38.99% from the prior year.
• Gross Profit rose to $14.1 million in Q1 2026 per SRTA's latest filing, from -$88.1 million in the prior quarter.
• Across five years, Gross Profit topped out at $69.2 million in Q2 2025 and bottomed at -$127.6 million in Q4 2023.
• The 5-year median for Gross Profit is $10.4 million (2023), against an average of -$3.8 million.
• The widest annual swing landed in 2022, when Gross Profit soared 1582.25%; it then tumbled 85.72% in 2025.
• Tracing SRTA's Gross Profit over 5 years: stood at $5.1 million in 2022, then plunged by 2595.7% to -$127.6 million in 2023, then jumped by 37.43% to -$79.8 million in 2024, then retreated by 10.42% to -$88.1 million in 2025, then jumped by 116.02% to $14.1 million in 2026.
• Per Business Quant, the three latest SRTA Gross Profit figures stand at $14.1 million (Q1 2026), -$88.1 million (Q4 2025), and $11.6 million (Q3 2025).

Peer Comparison